IP Verse

Adeno-Associated For Therapeutic Delivery To Central Nervous System - EP3294323

The patent EP3294323 was granted to Belur on Oct 13, 2021. The application was originally filed on May 13, 2016 under application number EP16797013A. The patent is currently recorded with a legal status of "Opposition Rejected".

EP3294323

BELUR
Application Number
EP16797013A
Filing Date
May 13, 2016
Status
Opposition Rejected
Feb 2, 2024
Publication Date
Oct 13, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

MAIWALDJul 13, 2022MAIWALDADMISSIBLE

Patent Citations (18) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS5656785
DESCRIPTIONUS5658776
DESCRIPTIONUS8609088
DESCRIPTIONWO2008049588
DESCRIPTIONWO2014186579
DESCRIPTIONWO9413788
DESCRIPTIONWO9513392
DESCRIPTIONWO9617947
DESCRIPTIONWO9823018
DESCRIPTIONWO9827204
INTERNATIONAL-SEARCH-REPORTUS2014088179
INTERNATIONAL-SEARCH-REPORTWO2014186579
INTERNATIONAL-SEARCH-REPORTWO2015013148
OPPOSITIONWO2014186579
OPPOSITIONWO2016187017
SEARCHUS2012009268
SEARCHUS2012288489
SEARCHUS2013039888

Non-Patent Literature (NPL) Citations (12) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- LAOHARAWEE et al., "AAV9 Mediated Correction of Iduronate- 2-Sulfatase Deficiency in the Central Nervous System of Mucopolysaccharidosis Type II Mice", Molecular Therapy, (20150501), vol. 23, page S146, XP055946938
OPPOSITION- Lebkowski Jane S, "American Society of Gene & Cell Therapy 18th Annual Meeting", Molecular Therapy, (20150501), vol. 23, no. S1, pages 1 - 14, XP093103823
OPPOSITION- NEUFELD et al., "The Mucopolysaccharidoses", Online Metabolic & Molecular Bases of Inherited Disease, (20010101), pages 3421 - 3452, XP009167340
OPPOSITION- Niemir Natalia, "Gene transfer in the Sandhoff murine model using a specific recombinant AAV9 vector", These UNIVERSITE PARIS DESCARTES, (20131125), pages 1 - 209, XP055946956
OPPOSITION- Polito Vinicia Assunta, "IDS crossing of the Blood-Brain Barrier corrects CNS defects in MPSII mice", Thesis EUROPEAN SCHOOL OF MOLECULAR MEDICINE NAPLES SITE, (20100101), pages 1 - 82, URL: http://www.fedoa.unina.it/4310/1/Polito.pdf, XP055946947
OPPOSITION- Polito Vinicia Assunta, Maria Pia Cosma, "IDS Crossing of the Blood-Brain Barrier Corrects CNS Defects in MPSII Mice", American Journal Human Genetic (Supplemental Data), (20090801), pages 1 - 9, XP093102632
OPPOSITION- RODER et al., NEUROCOGNITION AND SOCIAL COGNITION IN SCHIZOPHRENIA PATIENTS, (20100101), vol. 177
OPPOSITION- Rodriguiz Ramona Marie, William C Wetsel, "Chapter 12 Assessments of Cognitive Deficits in Mutant Mice", Rodriguiz Ramona Marie, William C Wetsel, Levin E D, Buccafusco J J, Animal Models of Cognitive Impairment, CRC Press/Taylor & Francis, (20060101), pages 1 - 53, XP093102630
OPPOSITION- Vinicia Assunta Polito, and Maria Pia Cosma, "IDS Crossing of the Blood-Brain Barrier Corrects CNS Defects in MPSII Mice", The American Journal of Human Genetics, US , (20090814), vol. 85, no. 2, doi:10.1016/j.ajhg.2009.07.011, ISSN 0002-9297, pages 296 - 301, XP002692097
OPPOSITION- Kanut Laoharawee, Kelly M. Podetz-Pedersen, Tam T. Nguyen, Laura B. Evenstar, Kelley F. Kitto, Zhenhong Nan, Carolyn A. Fairbanks, Walter C. Low, Karen F. Kozarsky, R. Scott Mcivor, "Prevention of Neurocognitive Deficiency in Mucopolysaccharidosis Type II Mice by Central Nervous System–Directed, AAV9-Mediated Iduronate Sulfatase Gene Transfer", Human Gene Therapy, GB , (20170801), vol. 28, no. 8, doi:10.1089/hum.2016.184, ISSN 1043-0342, pages 626 - 638, XP055401129
OPPOSITION- LAOHARAWEE et al., "Prevention of Neurocognitive Deficiency in Mucopolysaccharidosis Type II Mice by Central Nervous System-Directed, AAV9-Mediated Iduronate Sulfatase Gene Transfer", Human Gene Therapy, (20170505), vol. 28, no. 8, doi:10.1089/hum.2016.184, pages 626 - 638, XP055401129
OPPOSITION- WOLF et al., "Gene Therapy for Neurologic Manifestations of Mucopolysaccharidoses", Expert Opin Drug Deliv, (20141216), vol. 12, no. 2, doi:10.1517/17425247.2015.966682, pages 283 - 296, XP055401272

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents